Pregnancy

Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch

- Topline results from FemaSeed® pivotal trial expected in 1H 2024 - - Commercial launch planned for early 2024 -…

1 year ago

Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)

GAITHERSBURG, Md., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research…

1 year ago

Global COVID-19 Monument Design Competition Winner Announced

These Frontline workers deserve a monument, Please donate $10 to honor them today! Casey Schachner COVID-19 Monument Design Contest winner…

1 year ago

Moreno Valley Physicians Associates Empowers Patients and Improves Communication Through Integration with eClinicalWorks AI Tools

New eClinicalWorks AI assistant tools are improving patient satisfaction and care with multi-language supportWESTBOROUGH, Mass.--(BUSINESS WIRE)--eClinicalWorks®, the largest ambulatory cloud…

1 year ago

Trevena Reports Third Quarter 2023 Results and Provides Business Update

Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target…

1 year ago

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

Conference Call and Webcast Today at 4:30 p.m. ET What to Expect for the Remainder of 2023 XACIATO™: receipt of…

1 year ago

Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI®(sparsentan) in IgAN and Phase 3 DUPLEX Study…

1 year ago

Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting

Studies address cost-effectiveness and budget impact of INPEFA, an inhibitor of SGLT2 and SGLT1 INPEFA recently approved by FDA for treatment…

1 year ago

Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society’s Annual Meeting at ObesityWeek ®

BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the…

1 year ago